^
Association details:
| Biomarker: | ROS1 wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical Outcome of Neoadjuvant of Tislelizumab Plus Chemotherapy for Chinese Locally Advanced NSCLC Patients
Published date:
08/08/2023
Excerpt:
We enrolled 24 IIB-IIIC NSCLC patients who did not harbore any EGFR, ALK and ROS-1 driver mutations were treated with Tislelizumab plus chemotherapy...After surgery, pathological response were evaluated and MPR was 37.5%, pCR was 29.2%....Tislelizumab plus chemotherapy were effective in early or locally advanced NSCLC patients as neoadjuvant treatment.
Secondary therapy:
Chemotherapy
